AMSilk, based in Munich, has raised an additional $27,344,000 in its Series C round. The funding round was led by Novo Holdings with participation from MiG Capital and Cargill. The new funds will be used to expand the industrial product and distribution of the company's bio-fabricated silk protein materials, according to the company.

AMSilk is the world's first industrial supplier of smart biotech materials in the scale-up phase, using an outstanding technology protein platform based on silk proteins for a wide range of applications including textile fibers, medical devices, and consumer goods. Through its customizable solutions, the Company strives to make smart biotech materials a part of everyday life.

"We are delighted to have closed this successful financing round, which validates our technology and supports our ongoing development as we scale up and expand our commercial operations," said Ulrich Scherbel, CEO of AMSilk. "We will invest in technology to ensure that we continue to provide innovative, appealing solutions to our customers, as well as to improve the commercial supply of our products in order to grow our business."